# Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

> **NCT00395421** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 114 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** NM283 plus Peg-IFNα-2a

## Key facts

- **NCT ID:** NCT00395421
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-06
- **Final completion:** 2008-08
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2010-06-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00395421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00395421, "Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT00395421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*